文献速递自身免疫性与大疱性皮肤病银屑病与炎症性皮肤病

免疫介导性皮肤病患者接种ChAdOx1-S[重组]疫苗的免疫原性与反应原性真实世界前瞻性队列研究

A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
PubMed 文献 · Br J Dermatol · 2023-01-01

该前瞻性队列研究纳入127例免疫介导性皮肤病(IMDD)患者和97名无免疫介导疾病对照,接种ChAdOx1-S[重组]疫苗后1个月评估SARS-CoV-2特异性免疫与副作用。IMDD组血清转阳率与对照组相似(75.6% vs 84.5%,P=0.101),但干扰素-γ释放试验阳性率较低(72.4% vs 88.7%,P=0.003);大疱性自身免疫病患者免疫原性最低,银屑病患者最高。

要点

  • IMDD患者接种后血清转阳率与对照相似,但T细胞免疫阳性率较低。
  • 大疱性自身免疫病患者免疫原性最低(SR 64.5%,+IGRA 62.9%)。
  • 银屑病患者免疫原性最高(SR 87.7%,+IGRA 80.7%)。

核心结论

  • 在IMDD参与者中,ChAdOx1-S[重组]对银屑病患者显示良好免疫原性,但对大疱性自身免疫病患者免疫原性较低。
  • 部分患者尤其是大疱性自身免疫病患者需密切监测,因其可能在接种后1个月内需要治疗升级。

研究设计与样本

  • 前瞻性队列研究,纳入127例IMDD患者和97名无免疫介导疾病参与者,均接种ChAdOx1-S[重组]疫苗。
  • 接种后1个月评估SARS-CoV-2特异性免疫和副作用特征,并在组间比较。

主要发现

  • IMDD组血清转阳率与无免疫介导疾病组相似(75.6% vs 84.5%,P=0.101)。
  • IMDD组干扰素-γ释放试验阳性率低于无免疫介导疾病组(72.4% vs 88.7%,P=0.003)。
  • 两组反应原性相似,未报告严重不良反应。
  • 按疾病分层,大疱性自身免疫病患者免疫原性最低(SR 64.5%,+IGRA 62.9%),银屑病患者最高(SR 87.7%,+IGRA 80.7%);疫苗相关反应呈相反趋势。
  • 15.8%的IMDD患者免疫抑制剂升级,其中75%为大疱性自身免疫病患者。

关键数值与推荐

  • 免疫学主要结局:中和抗体阳性率(血清转阳率)和干扰素-γ释放试验阳性率(+IGRA)。
  • 反应原性次要结局:未列出的不良反应和接种期间及接种后1个月内免疫抑制剂升级反映的IMDD活动恶化。

临床怎么用

  • 作者认为,部分IMDD患者尤其是大疱性自身免疫病患者在接种后1个月内可能需要治疗升级,应密切监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunogenicity and reactogenicity of COVID-19 vaccines have been established in various groups of immunosuppressed patients; however, studies involving patients with immune-mediated dermatological diseases (IMDDs) are scarce. OBJECTIVES: To investigate the influence of IMDDs on the development of SARS-CoV-2-specific immunity and side-effects following ChAdOx1-S[recombinant] vaccination. METHODS: This prospective cohort study included 127 patients with IMDDs and 97 participants without immune-mediated diseases who received ChAdOx1-S[recombinant]. SARS-CoV-2-specific immunity and side-effect profiles were assessed at 1 month postvaccination and compared between groups. Immunological (primary) outcomes were the percentages of participants who tested positive for neutralizing antibodies [seroconversion rate (SR)] and those who developed T-cell-mediated immunity demonstrated by an interferon-γ-releasing assay (IGRA) [positive IGRA rate (+IGRA)]. Reactogenicity-related (secondary) outcomes were the unsolicited adverse reactions and worsening of IMDD activity reflected by the uptitration of immunosuppressants during and within 1 month of vaccination. RESULTS: Overall, the SR for the IMDD group was similar to that of participants without immune-mediated conditions (75·6 vs. 84·5, P = 0·101), whereas + IGRA was lower (72·4 vs. 88·7, P = 0·003). Reactogenicity was similar between groups. No severe adverse reaction was reported. By stratifying the participants in the IMDD group according to individual disease, the immunogenicity of the vaccine was lowest in patients with autoimmune bullous diseases (AIBD) (SR 64·5%, +IGRA 62·9%) and highest in patients with psoriasis (SR 87·7%, +IGRA 80·7%). The reverse trend was found for vaccine-related reactions. Immunosuppressants were uptitrated in 15·8% of cases; 75% of these were patients with AIBD. CONCLUSIONS: Among participants with IMDDs, ChAdOx1-S[recombinant] showed good immunogenicity among patients with psoriasis, but demonstrated lower levels of immunogenicity for patients with AIBD. Some patients, especially patients with AIBD, should be closely monitored as they may require treatment escalation within 1 month postvaccination.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, et al. A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases. Br J Dermatol. 2023. PMID: 36637102. doi:10.1093/bjd/ljac045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。